Zhang Jiaqi Amber, Nizet Victor
The Bishop's School, La Jolla, CA 92037, USA.
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Vaccines (Basel). 2025 Aug 23;13(9):893. doi: 10.3390/vaccines13090893.
Antibiotics have dramatically reduced the burden of infectious diseases since their discovery, but the accelerating rise in antimicrobial resistance (AMR) now threatens these gains. AMR was responsible for nearly 5 million deaths in 2023 and continues to undermine the efficacy of existing treatments, particularly in low- and middle-income countries. While efforts to address AMR have focused heavily on antibiotic stewardship and new drug development, vaccines represent a powerful yet underutilized tool for prevention. By reducing the incidence of bacterial infections, vaccines lower antibiotic consumption, interrupt transmission of resistant strains, and minimize the selective pressures that drive resistance. Unlike antibiotics, vaccines offer long-lasting protection, rarely induce resistance, and confer indirect protection through herd immunity. This review examines the global burden and drivers of AMR, highlights the unique advantages of vaccines over antibiotics in mitigating AMR, and surveys the current development pipeline of vaccines targeting key multidrug-resistant bacterial pathogens.
自抗生素被发现以来,它们极大地减轻了传染病的负担,但抗菌药物耐药性(AMR)的加速上升如今正威胁着这些成果。2023年,AMR导致了近500万人死亡,并且仍在削弱现有治疗方法的疗效,尤其是在低收入和中等收入国家。虽然应对AMR的努力主要集中在抗生素管理和新药开发上,但疫苗是一种强大却未得到充分利用的预防工具。通过降低细菌感染的发生率,疫苗减少了抗生素的使用,阻断了耐药菌株的传播,并将推动耐药性产生的选择压力降至最低。与抗生素不同,疫苗提供持久的保护,很少诱导耐药性,并通过群体免疫提供间接保护。本综述探讨了AMR的全球负担和驱动因素,强调了疫苗在减轻AMR方面相对于抗生素的独特优势,并调查了针对关键多重耐药细菌病原体的疫苗目前的研发情况。